Loading…

Kidney and Thyroid Cancer-Specific Treatment Algorithm for Spinal Metastases: A Validation Study

Spinal metastases (SMs) from kidney and thyroid cancers have several common features suggesting that excisional surgery for isolated and removable SMs can improve survival. We propose a simple treatment algorithm for SMs from these cancers. Our study aimed to evaluate the efficacy of the algorithm....

Full description

Saved in:
Bibliographic Details
Published in:World neurosurgery 2019-02, Vol.122, p.e1305-e1311
Main Authors: Kato, Satoshi, Murakami, Hideki, Demura, Satoru, Yoshioka, Katsuhito, Yokogawa, Noriaki, Yonezawa, Noritaka, Shimizu, Takaki, Oku, Norihiro, Kitagawa, Ryo, Tsuchiya, Hiroyuki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Spinal metastases (SMs) from kidney and thyroid cancers have several common features suggesting that excisional surgery for isolated and removable SMs can improve survival. We propose a simple treatment algorithm for SMs from these cancers. Our study aimed to evaluate the efficacy of the algorithm. We performed a retrospective analysis of the data of 69 consecutive patients (48 with kidney and 21 with thyroid cancers) who underwent excisional surgery for SMs between 1995 and 2014. The patients were retrospectively classified into an indicated group for excisional SM surgery and a nonindicated group according to our algorithm, and the Tokuhashi and Tomita scoring systems. Patients in the indicated group were expected to survive ≥2 years postoperatively, whereas those in the nonindicated group were not. The positive predictive value and negative predictive value (NPV) were calculated using the predicted versus actual survival times of the patients. Survival was defined as the time from the first excisional surgery for the spinal lesion to death or the last follow-up of ≥2 years. For patients with kidney cancer, the 2- and 5-year survival rates were 85.4% and 60.4%, respectively. For patients with thyroid cancer, the 2- and 5-year survival rates were 100% and 83.8%, respectively. Our algorithm had a compatible high positive predictive value (95.5%) and NPV (100%), whereas the Tokuhashi and Tomita scoring systems had low NPVs of 15.8% and 13.3%, respectively. Our treatment algorithm of SMs from kidney and thyroid cancers is useful for determining an adequate treatment including excisional surgery.
ISSN:1878-8750
1878-8769
DOI:10.1016/j.wneu.2018.11.040